Qualifications
- MD
- PGDip
- PhD / DPhil (Imperial College London)
- MD
Summary
I am a Clinical Oncologist by training with a research doctorate in molecular imaging. I have a wide range of experience having worked for the NHS, academia and industry. I qualified in medicine (MB BS) from Madras University, India and completed a post graduate diploma in radiotherapy (DMRT) in 1991. My specialist training in clinical oncology was completed in Merseyside, UK being admitted as a Fellow of the Royal College of radiologists (FRCR) in 2004 and registered as a Clinical Oncologist in the General Medical Council Specialist Register. Between 1997 and 2000, I did my research fellowship at the Medical Research Council (MRC) Cyclotron Unit, Hammersmith Hospital, London between 1997 and 2000, evaluating the utility of positron emission tomography (PET) in anti-cancer drug development to obtain my PhD.
I was a Senior Clinical Research Fellow at the University of Manchester Wolfson Molecular Imaging Centre and an Honorary Consultant in Clinical Oncology at the Christie Hospital between 2005 and 2009. In 2009, I joined the GlaxoSmithKline Clinical Imaging Centre at the Hammersmith Hospital to lead the oncology imaging programme and as an honorary senior clinical lecturer at Imperial College. From 2011 to 2017, I headed oncology and respiratory medicine at Imanova Centre for Imaging Sciences, an Imperial College, University College London, Kings College London and MRC joint venture which aimed to provide imaging expertise to academia and commercial organisations. From 2018, I was the UK Head of Oncology at Invicro, a Konica Minolta Company.
In December 2019, I joined the Hull York Medical School and the University of Hull. I am the Clinical Research Lead at the Hull Molecular Imaging Centres (HuMIC), a > £15 million investment by the Daisy Charity Appeal together with the University of Hull and the Hull University Teaching Hospitals NHS Trust, developed to support radiotracer discovery and translational imaging at Hull. I am also an honorary consultant at the Hull University Teaching Hospital NHS Trust with a specialist practice in pulmonary oncology.
Journal Article
Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease
Helo, Y., Searle, G. E., Borghese, F., Abraham, S., & Saleem, A. (2020). Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease. EJNMMI Research, 10(1), Article 147. https://doi.org/10.1186/s13550-020-00736-9
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome
Jimenez-Royo, P., Bombardieri, M., Ciurtin, C., Kostapanos, M., Tappuni, A. R., Jordan, N., …Tarzi, R. (2021). Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology, 60(5), 2396-2408. https://doi.org/10.1093/rheumatology/keaa624
A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor
Maher, T. M., Simpson, J. K., Porter, J. C., Wilson, F. J., Chan, R., Eames, R., …Vahdati-Bolouri, M. (2020). A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respiratory Research, 21(1), Article 75. https://doi.org/10.1186/s12931-020-01339-7
Integrin αvβ6 Positron Emission Tomography Imaging in Lung Cancer Patients Treated With Pulmonary Radiation Therapy
Saleem, A., Helo, Y., Win, Z., Dale, R., Cook, J., Searle, G. E., & Wells, P. (2020). Integrin αvβ6 Positron Emission Tomography Imaging in Lung Cancer Patients Treated With Pulmonary Radiation Therapy. International journal of radiation oncology, biology, physics, 107(2), 370-376. https://doi.org/10.1016/j.ijrobp.2020.02.014
Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
Lukey, P. T., Coello, C., Gunn, R., Parker, C., Wilson, F. J., Saleem, A., …Marshall, R. P. (2020). Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). European journal of nuclear medicine and molecular imaging, 47(4), 967-979. https://doi.org/10.1007/s00259-019-04586-z